University of Groningen

Complications and optimisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease

Buurman, Dorien Joke

DOI:
[10.33612/diss.98535663](https://doi.org/10.33612/diss.98535663)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Buurman, D. J. (2019). *Complications and optimisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen. <https://doi.org/10.33612/diss.98535663>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

**Complications and optimisation of
Mesalazine and anti-TNF-alpha therapy in
inflammatory bowel disease**

D.J. Buurman

Complications and optimisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease

ISBN: 978-94-034-1928-2

ISBN: 978-94-034-1929-9 (Electronic version)

Cover design: Helga de Graaf, Studio Eye Candy

Cover artwork: Mount Fuji, Katsushika Hokusai (1760–1849)

Layout: Helga de Graaf, Studio Eye Candy

Printed by Ipskamp Printing

This thesis was financially supported by the Graduate School of Medical Sciences.

Copyright © 2019 D.J. Buurman

All right reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.

rijksuniversiteit
groningen

Complications and optimisation of Mesalazine and anti-TNF-alpha therapy in inflammatory bowel disease

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 6 november 2019 om 16.15 uur

door

Dorien Joke Buurman

geboren op 4 oktober 1983
te Emmen

Promotores

Prof. dr. G. Dijkstra

Prof. dr. R.K. Weersma

Beoordelingscommissie

Prof. dr. H.J. Verkade

Prof. dr. C.J. van der Woude

Prof. dr. C.Y. Ponsioen

Paranimfen

S.T. Buurman

S. Baas-Brunen

Table of contents

Chapter 1	Introduction	9
-----------	--------------	---

Part I: Mesalazine

Chapter 2	Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study <i>Scan J Gastroenterology 2015 Apr; 50(4): 399-405</i>	23
Chapter 3	Mesalazine luxated auto-immune hepatitis/small duct PSC overlap syndrome in an ulcerative colitis patient: case report and review of literature <i>Submitted</i>	37
Chapter 4	Clinical Features and HLA association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel disease <i>J Crohns Colitis 2016 Feb;10(2):149-58</i>	47

Part II: Anti-TNF-alpha

Chapter 5	Detection of infliximab levels and anti-infliximab antibodies: a Comparison of three different assays <i>Aliment Pharmacol Ther 2012;36:765-771</i>	69
Chapter 5a	Letter: Detection of infliximab levels and anti-infliximab antibodies: a Comparison of three different assays – authors'reply <i>Aliment Pharmacol Ther, 2013 Jan;37(2):282</i>	81
Chapter 6	Quantitative comparison of the neutralizing capacity, immunogenicity and cross reactivity of anti-TNF-alpha biologicals and an Infliximab-biosimilar <i>Plos One 2018 Dec 11;13(12)</i>	85

Chapter 7	Immunogenicity to anti-TNF alpha: a non-HLA association <i>Manuscript in preparation</i>	99
Chapter 8	Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice <i>Aliment Pharmacol Therapy 2015 sep; 42(5):529-39</i>	113
Chapter 8a	Letter: infliximab therapy for patients with inflammatory bowel disease: some unanswered questions - author's reply <i>Aliment Pharmacol Ther 2015 Nov;42(9):1134</i>	132
Chapter 9	Colopulse tablets perform comparably in healthy volunteers and Crohns's patients and show no influence of food and time of food intake on bioavailability <i>J Control Release 2013, Dec 28;172(3):619-24</i>	137
Chapter 10	Towards Mucosal Application of Infliximab in the Therapy of Enterocolitis (TOMATE) : a proof of concept study <i>Study protocol</i>	155
Chapter 11	Summary, discussion and future perspectives	175
Addendum	Samenvatting	188
	Dankwoord	192
	Curriculum vitae	195
	Bibliography	197